Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 92Neoplasm Metastasis 10Neoplasms 9Breast Diseases 4Advanced Breast Cancer 3Recurrence 2Neoplasms by Site 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Post Menopausal Women With Early Breast Cancer 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 1 1Mammary Neoplasms, Animal 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1Kidney Neoplasms 1Invasive Early Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Fulvestrant 13Letrozole 6Anastrozole 5palbociclib 4exemestane 3Injections 3Docetaxel 3Paclitaxel 2Goserelin 2Dasatinib 2Capecitabine 2Alpelisib 2AZD9833 2vandetanib 1ribociclib 1irinotecan sucrosofate 1entinostat 1elacestrant 1cediranib 1abemaciclib 1XMT-1522 1Vinorelbine 1Sirolimus 1Ritonavir 1Lead 1Itraconazole 1Immunotherapy, Adoptive 1Everolimus 1Decitabine 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer × exemestane × Clear all
NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Novartis

Phase 2 Completed
92 enrolled 9 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡